Table: Kyowa Kirin -9-MTH group results (IFRS)
Nov 4 (Reuters)-
Kyowa Kirin Co., Ltd.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Sep 30, 2022 Sep 30, 2021 Dec 31, 2022
LATEST YEAR-AGO COMPANY
RESULTS RESULT FORECAST
Sales 283.78 253.97 400.00
(+11.7 pct) (+8.5 pct) (+13.6 pct)
Operating
Pretax 60.40 41.89 79.00
(+44.2 pct) (-5.2 pct) (+31.6 pct)
Net 49.21 32.91 63.00
(+49.5 pct) (-12.2 pct) (+20.3 pct)
EPS Basic 91.57 yen 61.25 yen 117.22 yen
EPS Diluted 91.55 yen 61.22 yen
Ann Div 46.00 yen 48.00 yen
-Q2 Div 24.00 yen 23.00 yen
-Q4 Div 23.00 yen 24.00 yen
NOTE - Kyowa Kirin Co., Ltd..
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4151.T
Recent news on Kyowa Kirin
See all newsFactbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Brief: Kyowa Kirin Announces Agreement With US Administration To Reduce Treatment Costs For Americans
Table: Kyowa Kirin 6-MTH group results (IFRS)
Brief: Kyowa Kirin Says European Commission Approves Crysvita For Infants With X-Linked Hypophosphataemia